Company news

Shanghai Junshi Biosciences Co., Ltd. Class A (SSE:688180) news

Shanghai Junshi Biosciences Co., Ltd. Class A news releases on 6ix. Latest, Sep 24, 2026: "Shanghai Junshi Biosciences Co., Ltd."Announcement on Satisfaction…

Shanghai Junshi Biosciences Co., Ltd. Class A (SSE:688180) news

Press releases & updates

"Shanghai Junshi Biosciences Co., Ltd."Announcement on Satisfaction of Exercise Conditions for the 1st Exercise Period of the Initial Grant under the 2025 A-Share Stock Option Incentive Plan and Cancellation of Certain Stock Options

"Shanghai Junshi Biosciences Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

"Shanghai Junshi Biosciences Co., Ltd."Announcement on Shareholding Reduction Plan of Shareholder

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

"Shanghai Junshi Biosciences Co., Ltd."Announcement on Results of Issuance of the 3rd Tranche of Sci-Tech Innovation Bonds in 2026

"Shanghai Junshi Biosciences Co., Ltd."Announcement on Results of Shareholding Reduction by Shareholder

"Shanghai Junshi Biosciences Co., Ltd."Indicative Announcement on Change in Equity of Shareholders Holding More Than 5% of the Shares Reaching 1% Threshold

"Shanghai Junshi Biosciences Co., Ltd."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

"Shanghai Junshi Biosciences Co., Ltd."Announcement on Results of Issuance of the Second Tranche of Sci-Tech Innovation Bonds in 2026

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

"Shanghai Junshi Biosciences Co., Ltd."Notice on Convening the 1st Extraordinary General Meeting in 2026

"Shanghai Junshi Biosciences Co.,Ltd."Announcement on Signing of an Authorization and License Agreement with Fosun Wanbang

Announcement on Resolutions of the 2025 Annual General Meeting

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

Notice on Convening the 2025 Annual General Meeting

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

Announcement on Resolutions of the 19th Meeting of the 4th Board of Directors

Announcement on Shareholding Reduction Plan of Shareholders

Announcement on Increasing Implementation Subject of Sub-Projects of Some Investment Projects Financed by Raised Funds

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

Announcement on Expiration of Shareholding Reduction Plan for Shareholders with Over 5% Shares and Non-Execution of Shareholding Reduction

Announcement on Result of Share Increase by the Controlling Shareholder and Actual Controller & Chairman, and the Equity Change Reaching the 1% Scale

Announcement on Convening the 2025 Annual Performance Briefing

Announcement on Voluntary Disclosure of Progress in Shareholding Increase for Controlling Shareholder, One of Actual Controllers and Chairman

Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates

Announcement on Return of Idle Raised Funds Temporarily Used to Supplement Current Capital

Announcement on Progress in Shareholding Increase for Controlling Shareholder, One of Actual Controllers and Chairman

Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications

Announcement on Preliminary Earnings Estimate for 2025

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)

Earnings Preannouncement for 2025

Announcement on the Results of Issuance of the 2026 Phase I Science and Technology Innovation Bonds

Announcement on Postponing Investment Projects Financed by Raised Funds

Announcement on Receipt of the "Notice of Registration Acceptance" from the National Association of Financial Market Institutional Investors

Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares

Announcement on Voluntary Disclosure of the FDA Approval of Clinical Trial Application for JS212

Announcement on Voluntary Disclosure of New Indication of Tuoyi® and the Inclusion of Junshida® in the National Medical Insurance Catalog

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Announcement on Result of Shareholding Reduction by Shareholder with Over 5% Shares

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 5% Scale

Announcement on Using Temporarily Idle Raised Funds for Cash Management

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

Announcement on Completion of Registration of Initial Grant under 2025 A-share Stock Option Incentive Plan

Report for Q3 2025

Announcement on Voluntary Disclosure of the Wholly-owned Subsidiary Passing On-site Inspection by FDA

Announcement on Convening the Q3 2025 Performance Briefing

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients